Eli Lilly (LLY) Non-Current Debt (2009 - 2026)

Eli Lilly (LLY) has reported Non-Current Debt for 18 consecutive years, with $39.4 billion the latest figure, recorded in Q1 2026.

• Non-Current Debt for Q1 2026 came in at $39.4 billion, up 14.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $39.4 billion (up 14.12% YoY), and the FY2025 annual result was $40.9 billion, up 43.26% from the prior year.
• Non-Current Debt was $39.4 billion for Q1 2026 at Eli Lilly, down from $40.9 billion in the prior quarter.
• Over five years, Non-Current Debt peaked at $40.9 billion in Q3 2025 and troughed at $14.1 billion in Q3 2022.
• Average Non-Current Debt over 5 years is $25.2 billion, with a median of $23.7 billion recorded in 2024.
• Year-over-year, Non-Current Debt dropped 8.88% in 2022 and soared 62.05% in 2024.
• Over 5 years, Non-Current Debt stood at $14.7 billion in 2022, then grew by 24.31% to $18.3 billion in 2023, then surged by 55.71% to $28.5 billion in 2024, then jumped by 43.26% to $40.9 billion in 2025, then declined by 3.67% to $39.4 billion in 2026.
• Per Business Quant data, the three most recent Non-Current Debt figures were $39.4 billion in Q1 2026, $40.9 billion in Q4 2025, and $40.9 billion in Q3 2025.